-
1
-
-
33751192457
-
Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study
-
Morange PE, Bickel C, Nicaud V, et al. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol. 2006;26:2793-2799.
-
(2006)
Arterioscler Thromb Vasc Biol
, vol.26
, pp. 2793-2799
-
-
Morange, P.E.1
Bickel, C.2
Nicaud, V.3
-
2
-
-
84855399476
-
Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A
-
Ragni MV, Moore CG. Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A. Haemophilia. 2011;17:867-871.
-
(2011)
Haemophilia
, vol.17
, pp. 867-871
-
-
Ragni, M.V.1
Moore, C.G.2
-
4
-
-
0035708764
-
Alternative methods for anticoagulation monitoring in pediatric patients with applicability to a patient with severe hemophilia A and circulating inhibitor
-
McNamara JL, Lombardi JP, Ferguson R, Manning PB, Gruppo RA. Alternative methods for anticoagulation monitoring in pediatric patients with applicability to a patient with severe hemophilia A and circulating inhibitor. J Extra Corpor Technol. 2001;33:239-242.
-
(2001)
J Extra Corpor Technol
, vol.33
, pp. 239-242
-
-
McNamara, J.L.1
Lombardi, J.P.2
Ferguson, R.3
Manning, P.B.4
Gruppo, R.A.5
-
5
-
-
84922824715
-
Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B
-
Ferraris VA, Boral LI, Cohen AJ, Smyth SS. Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B. Cardiol Rev. 2015;23:53-68.
-
(2015)
Cardiol Rev
, vol.23
, pp. 53-68
-
-
Ferraris, V.A.1
Boral, L.I.2
Cohen, A.J.3
Smyth, S.S.4
-
6
-
-
0035085485
-
Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa
-
Sheth S, Dimichele D, Lee M, et al. Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa. Haemophilia. 2001;7:227-232.
-
(2001)
Haemophilia
, vol.7
, pp. 227-232
-
-
Sheth, S.1
Dimichele, D.2
Lee, M.3
-
7
-
-
84963623112
-
A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects
-
Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127:1633-1641.
-
(2016)
Blood
, vol.127
, pp. 1633-1641
-
-
Uchida, N.1
Sambe, T.2
Yoneyama, K.3
-
8
-
-
85021675727
-
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
-
Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117:1348-1357.
-
(2017)
Thromb Haemost
, vol.117
, pp. 1348-1357
-
-
Kitazawa, T.1
Esaki, K.2
Tachibana, T.3
-
9
-
-
85028497303
-
Emicizumab prophylaxis in hemophilia A with inhibitors
-
Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809-818.
-
(2017)
N Engl J Med
, vol.377
, pp. 809-818
-
-
Oldenburg, J.1
Mahlangu, J.N.2
Kim, B.3
-
10
-
-
85052877162
-
Kruse-jarres R: emicizumab prophylaxis in patients who have hemophilia A without inhibitors
-
Mahlangu J, Oldenburg J, Paz-Priel I, et al. Kruse-jarres R: emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811-822.
-
(2018)
N Engl J Med
, vol.379
, pp. 811-822
-
-
Mahlangu, J.1
Oldenburg, J.2
Paz-Priel, I.3
-
11
-
-
85067976440
-
Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays
-
Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019;119:1084-1093.
-
(2019)
Thromb Haemost
, vol.119
, pp. 1084-1093
-
-
Adamkewicz, J.I.1
Chen, D.C.2
Paz-Priel, I.3
-
12
-
-
85032940097
-
Perioperative coagulation management of a hemophilia A patient during cardiac surgery
-
Odonkor P, Srinivas A, Strauss E, Williams B, Mazzeffi M, Tanaka KA. Perioperative coagulation management of a hemophilia A patient during cardiac surgery. Semin Cardiothorac Vasc Anesth. 2017;21:312-320.
-
(2017)
Semin Cardiothorac Vasc Anesth
, vol.21
, pp. 312-320
-
-
Odonkor, P.1
Srinivas, A.2
Strauss, E.3
Williams, B.4
Mazzeffi, M.5
Tanaka, K.A.6
-
13
-
-
85089447469
-
A pharmacokinetic and pharmacodynamic investigation of an epsilon-aminocaproic acid regimen designed for cardiac surgery with cardiopulmonary bypass
-
Strauss ER, Dahmane E, Judd M, et al. A pharmacokinetic and pharmacodynamic investigation of an epsilon-aminocaproic acid regimen designed for cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2021;35:406-417.
-
(2021)
J Cardiothorac Vasc Anesth
, vol.35
, pp. 406-417
-
-
Strauss, E.R.1
Dahmane, E.2
Judd, M.3
-
14
-
-
85095433881
-
Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: hAVEN 1 study
-
Schmitt C, Adamkewicz JI, Xu J, et al. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: hAVEN 1 study. Thromb Haemost. 2021;121:351-360.
-
(2021)
Thromb Haemost
, vol.121
, pp. 351-360
-
-
Schmitt, C.1
Adamkewicz, J.I.2
Xu, J.3
-
15
-
-
0036297734
-
The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation
-
table of contents
-
Koster A, Despotis G, Gruendel M, et al. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. Anesth Analg. 2002;95:26-30. table of contents.
-
(2002)
Anesth Analg
, vol.95
, pp. 26-30
-
-
Koster, A.1
Despotis, G.2
Gruendel, M.3
-
16
-
-
85065022519
-
Contradictory to its effects on thrombin, C1-inhibitor reduces plasmin generation in the presence of thrombomodulin
-
Tarandovskiy ID, Rajabi AA, Karnaukhova E, Buehler PW. Contradictory to its effects on thrombin, C1-inhibitor reduces plasmin generation in the presence of thrombomodulin. J Thromb Thrombolysis. 2019;48:81-87.
-
(2019)
J Thromb Thrombolysis
, vol.48
, pp. 81-87
-
-
Tarandovskiy, I.D.1
Rajabi, A.A.2
Karnaukhova, E.3
Buehler, P.W.4
-
17
-
-
85061621511
-
C1-esterase inhibitor enhances thrombin generation and spatial fibrin clot propagation in the presence of thrombomodulin
-
Tarandovskiy ID, Buehler PW, Ataullakhanov FI, Karnaukhova E. C1-esterase inhibitor enhances thrombin generation and spatial fibrin clot propagation in the presence of thrombomodulin. Thromb Res. 2019;176:54-60.
-
(2019)
Thromb Res
, vol.176
, pp. 54-60
-
-
Tarandovskiy, I.D.1
Buehler, P.W.2
Ataullakhanov, F.I.3
Karnaukhova, E.4
-
18
-
-
85061046022
-
Clinical impact of protamine titration-based heparin neutralization in patients undergoing coronary bypass grafting surgery
-
Abuelkasem E, Mazzeffi MA, Henderson RA, et al. Clinical impact of protamine titration-based heparin neutralization in patients undergoing coronary bypass grafting surgery. J Cardiothorac Vasc Anesth. 2019;33:2153-2160.
-
(2019)
J Cardiothorac Vasc Anesth
, vol.33
, pp. 2153-2160
-
-
Abuelkasem, E.1
Mazzeffi, M.A.2
Henderson, R.A.3
-
19
-
-
0030768838
-
Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation
-
Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg. 1997;85:498-506.
-
(1997)
Anesth Analg
, vol.85
, pp. 498-506
-
-
Despotis, G.J.1
Levine, V.2
Joist, J.H.3
Joiner-Maier, D.4
Spitznagel, E.5
-
20
-
-
77951668099
-
Monitoring heparin anticoagulation in the acute phase response
-
Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol. 2010;149:613-619.
-
(2010)
Br J Haematol
, vol.149
, pp. 613-619
-
-
Uprichard, J.1
Manning, R.A.2
Laffan, M.A.3
-
21
-
-
85065822161
-
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
-
Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6:e295-e305.
-
(2019)
Lancet Haematol
, vol.6
, pp. e295-e305
-
-
Pipe, S.W.1
Shima, M.2
Lehle, M.3
-
22
-
-
85090702853
-
Activated coagulation time and hepcon protamine titration device to manage unfractionated heparin during cardiopulmonary bypass in a hemophilia A patient on emicizumab
-
Isaacs J, Welsby IJ, Schroder JN, Onwuemene OA. Activated coagulation time and hepcon protamine titration device to manage unfractionated heparin during cardiopulmonary bypass in a hemophilia A patient on emicizumab. Journal of Cardiothoracic and Vascular Anesthesia. 2020. https://doi.org/10.1053/j.jvca.2020.08.058
-
(2020)
Journal of Cardiothoracic and Vascular Anesthesia
-
-
Isaacs, J.1
Welsby, I.J.2
Schroder, J.N.3
Onwuemene, O.A.4
-
23
-
-
55949104988
-
Inherited antithrombin deficiency: a review
-
Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 2008;14:1229-1239.
-
(2008)
Haemophilia
, vol.14
, pp. 1229-1239
-
-
Patnaik, M.M.1
Moll, S.2
-
24
-
-
8044257128
-
More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT
-
Despotis GJ, Joist JH. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost. 1996;76:902-908.
-
(1996)
Thromb Haemost
, vol.76
, pp. 902-908
-
-
Despotis, G.J.1
Joist, J.H.2
-
25
-
-
33750690191
-
Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography
-
Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia. 2006;12:598-604.
-
(2006)
Haemophilia
, vol.12
, pp. 598-604
-
-
Young, G.1
Blain, R.2
Nakagawa, P.3
Nugent, D.J.4
-
26
-
-
79955152951
-
Standardization of thromboelastography: a report from the TEG-ROTEM working group
-
Chitlur M, Sorensen B, Rivard GE, et al. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia. 2011;17:532-537.
-
(2011)
Haemophilia
, vol.17
, pp. 532-537
-
-
Chitlur, M.1
Sorensen, B.2
Rivard, G.E.3
-
27
-
-
85089006256
-
A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X
-
Ogiwara K, Nogami K, Matsumoto N, et al. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X. Int J Hematol. 2020;112:621-630.
-
(2020)
Int J Hematol
, vol.112
, pp. 621-630
-
-
Ogiwara, K.1
Nogami, K.2
Matsumoto, N.3
-
28
-
-
79151482034
-
Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux
-
Szlam F, Sreeram G, Solomon C, Levy JH, Molinaro RJ, Tanaka KA. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux. Thromb Res. 2011;127:135-140.
-
(2011)
Thromb Res
, vol.127
, pp. 135-140
-
-
Szlam, F.1
Sreeram, G.2
Solomon, C.3
Levy, J.H.4
Molinaro, R.J.5
Tanaka, K.A.6
-
29
-
-
13244253700
-
Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time
-
al Dieri R, Alban S, Beguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost. 2004;2:1395-1401.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 1395-1401
-
-
al Dieri, R.1
Alban, S.2
Beguin, S.3
Hemker, H.C.4
-
30
-
-
85071600045
-
Coagulation factor levels and underlying thrombin generation patterns in adult extracorporeal membrane oxygenation patients
-
Mazzeffi M, Strauss E, Meyer M, et al. Coagulation factor levels and underlying thrombin generation patterns in adult extracorporeal membrane oxygenation patients. Anesthesia & Analgesia. 2019:129.
-
(2019)
Anesthesia & Analgesia
, pp. 129
-
-
Mazzeffi, M.1
Strauss, E.2
Meyer, M.3
-
31
-
-
33645633454
-
Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass
-
Donahue BS, Gailani D, Mast AE. Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass. J Thromb Haemost. 2006;4:1011-1016.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 1011-1016
-
-
Donahue, B.S.1
Gailani, D.2
Mast, A.E.3
-
32
-
-
85020262076
-
Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay
-
Waters EK, Sigh J, Friedrich U, Hilden I, Sorensen BB. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia. 2017;23:769-776.
-
(2017)
Haemophilia
, vol.23
, pp. 769-776
-
-
Waters, E.K.1
Sigh, J.2
Friedrich, U.3
Hilden, I.4
Sorensen, B.B.5
-
33
-
-
85049331966
-
Factor IX from prothrombin complex concentrate augments low dose tissue factor-triggered thrombin generation in vitro
-
Hasan S, Abuelkasem E, Williams B, Henderson R, Mazzeffi MA, Tanaka KA. Factor IX from prothrombin complex concentrate augments low dose tissue factor-triggered thrombin generation in vitro. Br J Anaesth. 2018;121:936-943.
-
(2018)
Br J Anaesth
, vol.121
, pp. 936-943
-
-
Hasan, S.1
Abuelkasem, E.2
Williams, B.3
Henderson, R.4
Mazzeffi, M.A.5
Tanaka, K.A.6
-
34
-
-
85099057657
-
Hematologic evaluation of intraoperative autologous blood collection and allogeneic transfusion in cardiac surgery
-
Henderson RA, Judd M, Strauss ER, et al. Hematologic evaluation of intraoperative autologous blood collection and allogeneic transfusion in cardiac surgery. Transfusion. 2021;61:788-798.
-
(2021)
Transfusion
, vol.61
, pp. 788-798
-
-
Henderson, R.A.1
Judd, M.2
Strauss, E.R.3
-
35
-
-
82955164016
-
A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis
-
Geffen Mv, Loof A, Lap P, et al. A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis. Hematology. 2011;16:327-336.
-
(2011)
Hematology
, vol.16
, pp. 327-336
-
-
Geffen, M.1
Loof, A.2
Lap, P.3
-
36
-
-
79952987033
-
Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults
-
Simpson ML, Goldenberg NA, Jacobson LJ, Bombardier CG, Hathaway WE, Manco-Johnson MJ. Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults. Thromb Res. 2011;127:317-323.
-
(2011)
Thromb Res
, vol.127
, pp. 317-323
-
-
Simpson, M.L.1
Goldenberg, N.A.2
Jacobson, L.J.3
Bombardier, C.G.4
Hathaway, W.E.5
Manco-Johnson, M.J.6
-
37
-
-
84860319276
-
Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A
-
Foley JH, Nesheim ME, Rivard GE, Brummel-Ziedins KE. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A. Haemophilia. 2012;18:e316-22.
-
(2012)
Haemophilia
, vol.18
, pp. e316-e322
-
-
Foley, J.H.1
Nesheim, M.E.2
Rivard, G.E.3
Brummel-Ziedins, K.E.4
-
38
-
-
85042263254
-
Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution
-
Lee JM, Park EY, Kim KM, Won JC, Jung TK, Lee SK. Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution. J Int Med Res. 2018;46:873-882.
-
(2018)
J Int Med Res
, vol.46
, pp. 873-882
-
-
Lee, J.M.1
Park, E.Y.2
Kim, K.M.3
Won, J.C.4
Jung, T.K.5
Lee, S.K.6
|